Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Qelbree (viloxazine) and Vyvanse (lisdexamfetamine) are both medications used to treat attention-deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older. However, they belong to different medication classes. Qelbree is a selective norepinephrine reuptake inhibitor (NRI), while Vyvanse is a stimulant. Vyvanse is also FDA-approved to treat moderate-to-severe binge eating disorder (BED) in adults, whereas Qelbree is not. Qelbree is taken once daily and is not a controlled substance. In contrast, Vyvanse is a Schedule II controlled substance due to its high potential for misuse and dependence. Qelbree is only available as a brand-name medication, while Vyvanse is available in both brand and generic forms. Common side effects of Qelbree include sleep problems, headache, and nausea, while Vyvanse can cause a low appetite, difficulty sleeping, and dry mouth. Both medications have significant drug interactions, so be sure your prescriber and pharmacist have a complete list of your medications.
Qelbree (viloxazine)
Vyvanse (lisdexamfetamine)
Qelbree (viloxazine)
Vyvanse (lisdexamfetamine)
Summary of Qelbree vs. Vyvanse
Summary for Norepinephrine reuptake inhibitor (NRI)
Vyvanse, the brand name for lisdexamfetamine, is a stimulant medication. It's used to treat attention deficit-hyperactivity disorder (ADHD) in people 6 years and older. It can also treat binge eating disorder (BED) in adults. Vyvanse (lisdexamfetamine) comes as capsules and chewable tablets. It's taken once per day in the morning. The dosage starts low and gets adjusted based on how you respond to the medication. Common side effects include trouble sleeping and loss of appetite. Vyvanse (lisdexamfetamine) is a controlled substance because it has a high risk of misuse and dependency.